Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/59565
Type
ArticleCopyright
Restricted access
Embargo date
2099-12-31
Collections
Metadata
Show full item record
EVALUATION OF THE EFFECT OF OXAMNIQUINE, PRAZIQUANTEL AND A COMBINATION OF BOTH DRUGS ON THE INTRAMOLLUSCAN PHASE OF SCHISTOSOMA MANSONI
Author
Affilliation
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Laboratório de Esquistossomose. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Laboratório de Esquistossomose. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Moluscário. Belo Horizonte, MG, Brazil.
University of Glasgow. Glasgow, Scotland, UK.
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Laboratório de Esquistossomose. Belo Horizonte, MG, Brazil / Santa Casa de Misericórdia. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Laboratório de Esquistossomose. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Moluscário. Belo Horizonte, MG, Brazil.
University of Glasgow. Glasgow, Scotland, UK.
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Laboratório de Esquistossomose. Belo Horizonte, MG, Brazil / Santa Casa de Misericórdia. Belo Horizonte, MG, Brazil.
Abstract
The activity of oxamniquine (OXA), praziquantel (PZQ), and a combination of both drugs was evaluated at the intramolluscan phase of Schistosoma mansoni. Biomphalaria glabrata snails infected with S. mansoni were treated with 500 mg/kg OXA, 1000 mg/kg PZQ or with 250 mg/kg OXA and 500 mg/kg PZQ, in association, at the pre-patent and patent phases of infection. The results showed that either treatments with OXA or PZQ, alone, at the pre-patent period, delayed the parasite's development, increasing the pre-patent period by approximately 10 days. At the same pre-patent period, treatment with a combination of OXA/PZQ delayed the parasite's development even more, extending the pre-patent period up to 56 days. At the patent period, treatment with OXA and PZQ, alone, interrupted cercarial shedding. When the snails were treated with 1000 mg/kg PZQ, the cercarial production was re-established 15 days after treatment, but in lower numbers than those obtained before treatment, whereas the snails treated with 500 mg/kg OXA were able to shed cercariae in similar quantities to those observed before treatment. The association 250 mg/kg OXA + 500 mg/kg PZQ, at the patent period, not only discontinued cercarial shedding, but also led to the "cure" of the snails, showing a synergistic effect of this combination of drugs. These results suggest that this model will be useful for selection of resistant parasites, as well as for screening new anti schistosomal drugs.
Share